Among patients with recurrent or severe CDI, administration of RBX2660 via enema appears to be safe and effective.
Between 15 August 2013 and 16 December 2013, 40 patients were enrolled at 11 centres across the United States. Of those, 34 patients received at least one dose of RBX2660, and 31 finished the 6-month follow-up. Efficiency was 87.1% overall (16 with 1 dose and 11 with 2 doses). The most frequent 188 reported AEs were constipation, flatulence, diarrhoea, and abdominal pain/cramping. Over time, AEs became less frequent and more mild. Seven individuals had twenty significant adverse events (AEs), none of which were connected to the use of or administration of RBX2660.
Learn more about Clostridium here:
https://brainly.com/question/26777813
#SPJ4
